RA
OKUR

Rosalind Advisors’s OnKure Therapeutics OKUR Stock Holding History

Rosalind Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$684K Sell
150,000
-293,763
-66% -$1.26M 0.25% 29
2026
Q1 		$1.84M Sell
443,763
-286,725
-39% -$885K 0.74% 25
2025
Q4 		$2.12M Buy
+730,488
New +$2.19M 0.74% 24

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rosalind Advisors's OKUR Position: Q2 2026 in Review

Rosalind Advisors reduced its OnKure Therapeutics (OKUR) stake by 66% in Q2 2026, selling an estimated $1.26M and leaving 150,000 shares worth $684K. The position accounts for 0.25% of the portfolio, ranked #29.

Rosalind Advisors first reported a position in OKUR in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.12M in Q4 2025. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Rosalind Advisors held 150,000 shares of OnKure Therapeutics worth $684K as of Q2 2026.
  • Rosalind Advisors sold 293,763 OnKure Therapeutics shares in Q2 2026, an estimated $1.26M.
  • OnKure Therapeutics made up 0.25% of Rosalind Advisors's portfolio in Q2 2026, its #29 holding.
  • Rosalind Advisors first reported a position in OnKure Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Rosalind Advisors's OnKure Therapeutics position peaked at $2.12M in Q4 2025.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.